The $1 million medicine is coming.
On Thursday, a committee of experts invited by the FDA will meet outside Washington D.C. to review an experimental gene therapy from Spark Therapeutics (ONCE). Barring unexpected surprises, the experts will advise the FDA to approve the one-time shot, which will be used to treat a rare, inherited form of childhood blindness.
An FDA approval would be historic for both scientific and financial reasons. It would be the first true gene therapy — meant to replace or repair a defective gene — approved in the U.S. That would end an 18-year interregnum for the gene therapy field that began, tragically, with the death of a patient in a clinical trial.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect